Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46)
Clinical Information
Acetyldigitoxins - Cardioactive derivatives of lanatoside A or of DIGITOXIN. They are used for fast digitalization in congestive heart failure.
Acetyldigoxins - Alpha- or beta-acetyl derivatives of DIGOXIN or lanatoside C from Digitalis lanata. They are better absorbed and longer acting than digoxin and are used in congestive heart failure.
Aconitine - A C19 norditerpenoid alkaloid (DITERPENES) from the root of ACONITUM; DELPHINIUM and larkspurs. It activates VOLTAGE-GATED SODIUM CHANNELS. It has been used to induce ARRHYTHMIAS in experimental animals and it has anti-inflammatory and anti-neuralgic properties.
Adrenochrome - Pigment obtained by the oxidation of epinephrine.
Ajmaline - An alkaloid found in the root of RAUWOLFIA SERPENTINA, among other plant sources. It is a class 1-A antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials.
Alprostadil - A potent vasodilator agent that increases peripheral blood flow.
Amiodarone - An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
Aprindine - A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.
Aspirin, Dipyridamole Drug Combination - A drug combination of aspirin and dipyridamole that functions as a PLATELET AGGREGATION INHIBITOR, used to prevent THROMBOSIS and STROKE in TRANSIENT ISCHEMIC ATTACK patients.
Bencyclane - A vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects. Its mechanism may involve block of calcium channels.
Bepridil - A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
Betahistine - A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.
Bethanidine - A guanidinium antihypertensive agent that acts by blocking adrenergic transmission. The precise mode of action is not clear.
Bezafibrate - An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.
Bunaftine - N-Butyl-N-(2-(diethylamino)ethyl)-1-naphthamide. A proposed antiarrhythmic that prolongs myocardial refractory period and stabilizes cell membranes.
Calcium Channel Blockers - A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
Captopril - A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
Carbidopa - An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.
Chromonar - A coronary vasodilator agent.
Cilazapril - One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.
Clofibrate - A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)
Clonidine - An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
Colestipol - Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels.
Cyclandelate - A direct-acting SMOOTH MUSCLE relaxant used to dilate BLOOD VESSELS.
Deoxyepinephrine - Sympathomimetic, vasoconstrictor agent.
Deslanoside - Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.
Diazoxide - A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
Digitoxin - A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Digoxin - A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
Dihydralazine - 1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)
Dihydroergocornine - A 9,10alpha-dihydro derivative of ERGOTAMINE that contains isopropyl sidechains at the 2' and 5' positions of the molecule.
Dihydroergotamine - A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.
Dihydroergotoxine - A mixture of three different hydrogenated derivatives of ERGOTAMINE: DIHYDROERGOCORNINE; DIHYDROERGOCRISTINE; and DIHYDROERGOCRYPTINE. Dihydroergotoxine has been proposed to be a neuroprotective agent and a nootropic agent. The mechanism of its therapeutic actions is not clear, but it can act as an alpha-adrenergic antagonist and a dopamine agonist. The methanesulfonate salts of this mixture of alkaloids are called ERGOLOID MESYLATES.
Dilazep - Coronary vasodilator with some antiarrhythmic activity.
Diltiazem - A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.
Diosmin - A bioflavonoid that strengthens vascular walls.
Dipyridamole - A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Disopyramide - A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Enalapril - An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.
Enalaprilat - The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.
Encainide - One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.
Ergoloid Mesylates - A mixture of the mesylates (methane sulfonates) of DIHYDROERGOCORNINE; DIHYDROERGOCRISTINE; and the alpha- and beta-isomers of DIHYDROERGOCRYPTINE. The substance produces a generalized peripheral vasodilation and a fall in arterial pressure and has been used to treat symptoms of mild to moderate impairment of mental function in the elderly.
Ergotamine - A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.
Ergotamines - A series of structurally-related alkaloids containing the ergotaman backbone structure.
Erythrityl Tetranitrate - A vasodilator with general properties similar to NITROGLYCERIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
Felodipine - A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
Fendiline - Coronary vasodilator; inhibits calcium function in muscle cells in excitation-contraction coupling; proposed as antiarrhythmic and antianginal agents.
Fenofibrate - An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
Flecainide - A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
Flunarizine - Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Fosinopril - A phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.
Gallopamil - Coronary vasodilator that is an analog of iproveratril (VERAPAMIL) with one more methoxy group on the benzene ring.
Gemfibrozil - A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
Guanabenz - An alpha-2 selective adrenergic agonist used as an antihypertensive agent.
Guanethidine - An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
Guanfacine - A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Halofenate - An antihyperlipoproteinemic agent and uricosuric agent.
Heptaminol - An amino alcohol that has been used as a myocardial stimulant and vasodilator and to relieve bronchospasm. Its most common therapeutic use is in orthostatic hypotension. The mechanism of heptaminol's therapeutic actions is not well understood although it has been suggested to affect catecholamine release or calcium metabolism.
Hesperidin - A flavanone glycoside found in CITRUS fruit peels.
Hexobendine - A potent vasoactive agent that dilates cerebral and coronary arteries, but slightly constricts femoral arteries, without any effects on heart rate, blood pressure or cardiac output.
Hydralazine - A direct-acting vasodilator that is used as an antihypertensive agent.
Hyperkalemia - Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)
Iloprost - An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.
Indapamide - A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
Isosorbide Dinitrate - A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.
Isoxsuprine - A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Isradipine - A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Khellin - A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024)
Lanatosides - Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale, The Extra Pharmacopoeia, 30th ed, p670)
Lidoflazine - Coronary vasodilator with some antiarrhythmic action.
Linoleic Acid - A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed)
Linoleic Acids - Eighteen-carbon essential fatty acids that contain two double bonds.
Linoleic Acids, Conjugated - A collective term for a group of around nine geometric and positional isomers of LINOLEIC ACID in which the trans/cis double bonds are conjugated, where double bonds alternate with single bonds.
Linoleoyl-CoA Desaturase - An enzyme that catalyzes the syn-dehydrogenation of linoleol-CoA gamma-linolenoyl-CoA. It was formerly characterized as EC 1.14.99.25.
Lisinopril - One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.
Lorajmine - A monochloroacetyl derivative of ajmaline. It is a class Ia antiarrhythmic agent that is rapidly hydrolyzed to ajmaline by plasma and tissue esterases.
Lovastatin - A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
Methyldopa - An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.
Methysergide - An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.
Mexiletine - Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
Minoxidil - A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
Molsidomine - A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
Moxisylyte - An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)
Niacin - A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
Niacinamide - An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Nicardipine - A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
Nicergoline - An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It may ameliorate cognitive deficits in CEREBROVASCULAR DISORDERS.
Nicorandil - A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.
Nicotinyl Alcohol - Alcohol analog of NICOTINIC ACID which is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It is used in vasospasm and threatened GANGRENE.
Nifedipine - A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Nimodipine - A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
Nisoldipine - A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
Nitrendipine - A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
Nitroprusside - A powerful vasodilator used in emergencies to lower blood pressure or to improve cardiac function. It is also an indicator for free sulfhydryl groups in proteins.
Nylidrin - A beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.
Oleic Acid - An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed)
Oleic Acids - A group of fatty acids that contain 18 carbon atoms and a double bond at the omega 9 carbon.
Oxyfedrine - A drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent.
Pargyline - A monoamine oxidase inhibitor with antihypertensive properties.
Pentoxifylline - A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production.
Perindopril - An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.
Phenoxybenzamine - An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
Phentolamine - A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.
Pinacidil - A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)
Polidocanol - An alkyl polyglycol ether of LAURYL ALCOHOL, chemically defined as an alcohol ethoxylate having an average alkyl chain of 12–14 carbon atoms, and an ethylene oxide chain of 9 ethylene oxide units. It is used as a detergent, and medically as a local anesthetic, and as a sclerosing agent for the treatment of ESOPHAGEAL AND GASTRIC VARICES and VARICOSE VEINS.
Pravastatin - An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).
Prenylamine - A drug formerly used in the treatment of angina pectoris but superseded by less hazardous drugs. Prenylamine depletes myocardial catecholamine stores and has some calcium channel blocking activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1406)
Probucol - A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Procainamide - A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
Propafenone - An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
Proscillaridin - A cardiotonic glycoside isolated from Scilla maritima var. alba (Squill).
Pseudohypoaldosteronism - A heterogeneous group of disorders characterized by renal electrolyte transport dysfunctions. Congenital forms are rare autosomal disorders characterized by neonatal hypertension, HYPERKALEMIA, increased RENIN activity and ALDOSTERONE concentration. The Type I features HYPERKALEMIA with sodium wasting; Type II, HYPERKALEMIA without sodium wasting. Pseudohypoaldosteronism can be the result of a defective renal electrolyte transport protein or acquired after KIDNEY TRANSPLANTATION.
Quinapril - A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.
Quinidine - An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
Ramipril - A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.
Ricinoleic Acids - Eighteen carbon fatty acids that comprise the great majority of CASTOR OIL, which is from the seed of RICINUS.
Safflower Oil - An oily liquid extracted from the seeds of the safflower, Carthamus tinctorius. It is used as a dietary supplement in the management of HYPERCHOLESTEROLEMIA. It is used also in cooking, as a salad oil, and as a vehicle for medicines, paints, varnishes, etc. (Dorland, 28th ed & Random House Unabridged Dictionary, 2d ed)
Saralasin - An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION.
Simvastatin - A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
Sitosterols - A family of sterols commonly found in plants and plant oils. Alpha-, beta-, and gamma-isomers have been characterized.
Strophanthus - A plant genus of the family APOCYNACEAE that contains OUABAIN cardiac glycosides.
Suloctidil - A peripheral vasodilator that was formerly used in the management of peripheral and cerebral vascular disorders. It is hepatotoxic and fatalities have occurred. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)
Tadalafil - A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.
Teprotide - A synthetic nonapeptide (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) which is identical to the peptide from the venom of the snake, Bothrops jararaca. It inhibits kininase II and ANGIOTENSIN I and has been proposed as an antihypertensive agent.
Tocainide - An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.
Todralazine - An antihypertensive agent with both central and peripheral action; it has some central nervous system depressant effects.
Tolazoline - A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.
Trapidil - A coronary vasodilator agent.
Trimetazidine - A vasodilator used in angina of effort or ischemic heart disease.
Triparanol - Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.
Verapamil - A calcium channel blocker that is a class IV anti-arrhythmia agent.
Veratrine - A voltage-gated sodium channel activator.
Xanthinol Niacinate - A vasodilator used in peripheral vascular disorders and insufficiency. It may cause gastric discomfort and hypotension.
Instructional Notations
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
- poisoning by, adverse effect of and underdosing of metaraminol T44.4
7th Character Note
Certain ICD-10-CM categories have applicable 7th characters. The applicable 7th character is required for all codes within the category, or as the notes in the Tabular List instruct. The 7th character must always be the 7th character in the data field. If a code that requires a 7th character is not 6 characters, a placeholder X must be used to fill in the empty characters.
- The appropriate 7th character is to be added to each code from category T46
7th Character
Indicates that a seventh character is to be assigned to codes in a subcategory.
- A - initial encounter
- D - subsequent encounter
- S - sequela
Injury, poisoning and certain other consequences of external causes (S00–T88)
Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances (T36-T50)
T46 Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system
T46.0 Poisoning by, adverse effect of and underdosing of cardiac-stimulant glycosides and drugs of similar action
T46.0X Poisoning by, adverse effect of and underdosing of cardiac-stimulant glycosides and drugs of similar action
T46.0X1 Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional)
- T46.0X1A Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), initial encounter
- T46.0X1D Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), subsequent encounter
- T46.0X1S Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), sequela
T46.0X2 Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm
- T46.0X2A Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter
- T46.0X2D Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter
- T46.0X2S Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela
T46.0X3 Poisoning by cardiac-stimulant glycosides and drugs of similar action, assault
- T46.0X3A Poisoning by cardiac-stimulant glycosides and drugs of similar action, assault, initial encounter
- T46.0X3D Poisoning by cardiac-stimulant glycosides and drugs of similar action, assault, subsequent encounter
- T46.0X3S Poisoning by cardiac-stimulant glycosides and drugs of similar action, assault, sequela
T46.0X4 Poisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined
- T46.0X4A Poisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined, initial encounter
- T46.0X4D Poisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined, subsequent encounter
- T46.0X4S Poisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined, sequela
T46.0X5 Adverse effect of cardiac-stimulant glycosides and drugs of similar action
- T46.0X5A Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
- T46.0X5D Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
- T46.0X5S Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
T46.0X6 Underdosing of cardiac-stimulant glycosides and drugs of similar action
- T46.0X6A Underdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter
- T46.0X6D Underdosing of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
- T46.0X6S Underdosing of cardiac-stimulant glycosides and drugs of similar action, sequela
T46.1 Poisoning by, adverse effect of and underdosing of calcium-channel blockers
T46.1X Poisoning by, adverse effect of and underdosing of calcium-channel blockers
T46.1X1 Poisoning by calcium-channel blockers, accidental (unintentional)
- T46.1X1A Poisoning by calcium-channel blockers, accidental (unintentional), initial encounter
- T46.1X1D Poisoning by calcium-channel blockers, accidental (unintentional), subsequent encounter
- T46.1X1S Poisoning by calcium-channel blockers, accidental (unintentional), sequela
T46.1X2 Poisoning by calcium-channel blockers, intentional self-harm
- T46.1X2A Poisoning by calcium-channel blockers, intentional self-harm, initial encounter
- T46.1X2D Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter
- T46.1X2S Poisoning by calcium-channel blockers, intentional self-harm, sequela
T46.1X3 Poisoning by calcium-channel blockers, assault
- T46.1X3A Poisoning by calcium-channel blockers, assault, initial encounter
- T46.1X3D Poisoning by calcium-channel blockers, assault, subsequent encounter
- T46.1X3S Poisoning by calcium-channel blockers, assault, sequela
T46.1X4 Poisoning by calcium-channel blockers, undetermined
- T46.1X4A Poisoning by calcium-channel blockers, undetermined, initial encounter
- T46.1X4D Poisoning by calcium-channel blockers, undetermined, subsequent encounter
- T46.1X4S Poisoning by calcium-channel blockers, undetermined, sequela
T46.1X5 Adverse effect of calcium-channel blockers
- T46.1X5A Adverse effect of calcium-channel blockers, initial encounter
- T46.1X5D Adverse effect of calcium-channel blockers, subsequent encounter
- T46.1X5S Adverse effect of calcium-channel blockers, sequela
T46.1X6 Underdosing of calcium-channel blockers
- T46.1X6A Underdosing of calcium-channel blockers, initial encounter
- T46.1X6D Underdosing of calcium-channel blockers, subsequent encounter
- T46.1X6S Underdosing of calcium-channel blockers, sequela
T46.2 Poisoning by, adverse effect of and underdosing of other antidysrhythmic drugs, not elsewhere classified
T46.2X Poisoning by, adverse effect of and underdosing of other antidysrhythmic drugs
T46.2X1 Poisoning by other antidysrhythmic drugs, accidental (unintentional)
- T46.2X1A Poisoning by other antidysrhythmic drugs, accidental (unintentional), initial encounter
- T46.2X1D Poisoning by other antidysrhythmic drugs, accidental (unintentional), subsequent encounter
- T46.2X1S Poisoning by other antidysrhythmic drugs, accidental (unintentional), sequela
T46.2X2 Poisoning by other antidysrhythmic drugs, intentional self-harm
- T46.2X2A Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter
- T46.2X2D Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter
- T46.2X2S Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela
T46.2X3 Poisoning by other antidysrhythmic drugs, assault
- T46.2X3A Poisoning by other antidysrhythmic drugs, assault, initial encounter
- T46.2X3D Poisoning by other antidysrhythmic drugs, assault, subsequent encounter
- T46.2X3S Poisoning by other antidysrhythmic drugs, assault, sequela
T46.2X4 Poisoning by other antidysrhythmic drugs, undetermined
- T46.2X4A Poisoning by other antidysrhythmic drugs, undetermined, initial encounter
- T46.2X4D Poisoning by other antidysrhythmic drugs, undetermined, subsequent encounter
- T46.2X4S Poisoning by other antidysrhythmic drugs, undetermined, sequela
T46.2X5 Adverse effect of other antidysrhythmic drugs
- T46.2X5A Adverse effect of other antidysrhythmic drugs, initial encounter
- T46.2X5D Adverse effect of other antidysrhythmic drugs, subsequent encounter
- T46.2X5S Adverse effect of other antidysrhythmic drugs, sequela
T46.2X6 Underdosing of other antidysrhythmic drugs
- T46.2X6A Underdosing of other antidysrhythmic drugs, initial encounter
- T46.2X6D Underdosing of other antidysrhythmic drugs, subsequent encounter
- T46.2X6S Underdosing of other antidysrhythmic drugs, sequela
T46.3 Poisoning by, adverse effect of and underdosing of coronary vasodilators
T46.3X Poisoning by, adverse effect of and underdosing of coronary vasodilators
T46.3X1 Poisoning by coronary vasodilators, accidental (unintentional)
- T46.3X1A Poisoning by coronary vasodilators, accidental (unintentional), initial encounter
- T46.3X1D Poisoning by coronary vasodilators, accidental (unintentional), subsequent encounter
- T46.3X1S Poisoning by coronary vasodilators, accidental (unintentional), sequela
T46.3X2 Poisoning by coronary vasodilators, intentional self-harm
- T46.3X2A Poisoning by coronary vasodilators, intentional self-harm, initial encounter
- T46.3X2D Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter
- T46.3X2S Poisoning by coronary vasodilators, intentional self-harm, sequela
T46.3X3 Poisoning by coronary vasodilators, assault
- T46.3X3A Poisoning by coronary vasodilators, assault, initial encounter
- T46.3X3D Poisoning by coronary vasodilators, assault, subsequent encounter
- T46.3X3S Poisoning by coronary vasodilators, assault, sequela
T46.3X4 Poisoning by coronary vasodilators, undetermined
- T46.3X4A Poisoning by coronary vasodilators, undetermined, initial encounter
- T46.3X4D Poisoning by coronary vasodilators, undetermined, subsequent encounter
- T46.3X4S Poisoning by coronary vasodilators, undetermined, sequela
T46.3X5 Adverse effect of coronary vasodilators
- T46.3X5A Adverse effect of coronary vasodilators, initial encounter
- T46.3X5D Adverse effect of coronary vasodilators, subsequent encounter
- T46.3X5S Adverse effect of coronary vasodilators, sequela
T46.3X6 Underdosing of coronary vasodilators
- T46.3X6A Underdosing of coronary vasodilators, initial encounter
- T46.3X6D Underdosing of coronary vasodilators, subsequent encounter
- T46.3X6S Underdosing of coronary vasodilators, sequela
T46.4 Poisoning by, adverse effect of and underdosing of angiotensin-converting-enzyme inhibitors
T46.4X Poisoning by, adverse effect of and underdosing of angiotensin-converting-enzyme inhibitors
T46.4X1 Poisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional)
- T46.4X1A Poisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional), initial encounter
- T46.4X1D Poisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional), subsequent encounter
- T46.4X1S Poisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional), sequela
T46.4X2 Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm
- T46.4X2A Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter
- T46.4X2D Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter
- T46.4X2S Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela
T46.4X3 Poisoning by angiotensin-converting-enzyme inhibitors, assault
- T46.4X3A Poisoning by angiotensin-converting-enzyme inhibitors, assault, initial encounter
- T46.4X3D Poisoning by angiotensin-converting-enzyme inhibitors, assault, subsequent encounter
- T46.4X3S Poisoning by angiotensin-converting-enzyme inhibitors, assault, sequela
T46.4X4 Poisoning by angiotensin-converting-enzyme inhibitors, undetermined
- T46.4X4A Poisoning by angiotensin-converting-enzyme inhibitors, undetermined, initial encounter
- T46.4X4D Poisoning by angiotensin-converting-enzyme inhibitors, undetermined, subsequent encounter
- T46.4X4S Poisoning by angiotensin-converting-enzyme inhibitors, undetermined, sequela
T46.4X5 Adverse effect of angiotensin-converting-enzyme inhibitors
- T46.4X5A Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
- T46.4X5D Adverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter
- T46.4X5S Adverse effect of angiotensin-converting-enzyme inhibitors, sequela
T46.4X6 Underdosing of angiotensin-converting-enzyme inhibitors
- T46.4X6A Underdosing of angiotensin-converting-enzyme inhibitors, initial encounter
- T46.4X6D Underdosing of angiotensin-converting-enzyme inhibitors, subsequent encounter
- T46.4X6S Underdosing of angiotensin-converting-enzyme inhibitors, sequela
T46.5 Poisoning by, adverse effect of and underdosing of other antihypertensive drugs
T46.5X Poisoning by, adverse effect of and underdosing of other antihypertensive drugs
T46.5X1 Poisoning by other antihypertensive drugs, accidental (unintentional)
- T46.5X1A Poisoning by other antihypertensive drugs, accidental (unintentional), initial encounter
- T46.5X1D Poisoning by other antihypertensive drugs, accidental (unintentional), subsequent encounter
- T46.5X1S Poisoning by other antihypertensive drugs, accidental (unintentional), sequela
T46.5X2 Poisoning by other antihypertensive drugs, intentional self-harm
- T46.5X2A Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter
- T46.5X2D Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter
- T46.5X2S Poisoning by other antihypertensive drugs, intentional self-harm, sequela
T46.5X3 Poisoning by other antihypertensive drugs, assault
- T46.5X3A Poisoning by other antihypertensive drugs, assault, initial encounter
- T46.5X3D Poisoning by other antihypertensive drugs, assault, subsequent encounter
- T46.5X3S Poisoning by other antihypertensive drugs, assault, sequela
T46.5X4 Poisoning by other antihypertensive drugs, undetermined
- T46.5X4A Poisoning by other antihypertensive drugs, undetermined, initial encounter
- T46.5X4D Poisoning by other antihypertensive drugs, undetermined, subsequent encounter
- T46.5X4S Poisoning by other antihypertensive drugs, undetermined, sequela
T46.5X5 Adverse effect of other antihypertensive drugs
- T46.5X5A Adverse effect of other antihypertensive drugs, initial encounter
- T46.5X5D Adverse effect of other antihypertensive drugs, subsequent encounter
- T46.5X5S Adverse effect of other antihypertensive drugs, sequela
T46.5X6 Underdosing of other antihypertensive drugs
- T46.5X6A Underdosing of other antihypertensive drugs, initial encounter
- T46.5X6D Underdosing of other antihypertensive drugs, subsequent encounter
- T46.5X6S Underdosing of other antihypertensive drugs, sequela
T46.6 Poisoning by, adverse effect of and underdosing of antihyperlipidemic and antiarteriosclerotic drugs
T46.6X Poisoning by, adverse effect of and underdosing of antihyperlipidemic and antiarteriosclerotic drugs
T46.6X1 Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, accidental (unintentional)
- T46.6X1A Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, accidental (unintentional), initial encounter
- T46.6X1D Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, accidental (unintentional), subsequent encounter
- T46.6X1S Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, accidental (unintentional), sequela
T46.6X2 Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm
- T46.6X2A Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter
- T46.6X2D Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter
- T46.6X2S Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela
T46.6X3 Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, assault
- T46.6X3A Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, assault, initial encounter
- T46.6X3D Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, assault, subsequent encounter
- T46.6X3S Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, assault, sequela
T46.6X4 Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, undetermined
- T46.6X4A Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, undetermined, initial encounter
- T46.6X4D Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, undetermined, subsequent encounter
- T46.6X4S Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, undetermined, sequela
T46.6X5 Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs
- T46.6X5A Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
- T46.6X5D Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
- T46.6X5S Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
T46.6X6 Underdosing of antihyperlipidemic and antiarteriosclerotic drugs
- T46.6X6A Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
- T46.6X6D Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
- T46.6X6S Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, sequela
T46.7 Poisoning by, adverse effect of and underdosing of peripheral vasodilators
T46.7X Poisoning by, adverse effect of and underdosing of peripheral vasodilators
T46.7X1 Poisoning by peripheral vasodilators, accidental (unintentional)
- T46.7X1A Poisoning by peripheral vasodilators, accidental (unintentional), initial encounter
- T46.7X1D Poisoning by peripheral vasodilators, accidental (unintentional), subsequent encounter
- T46.7X1S Poisoning by peripheral vasodilators, accidental (unintentional), sequela
T46.7X2 Poisoning by peripheral vasodilators, intentional self-harm
- T46.7X2A Poisoning by peripheral vasodilators, intentional self-harm, initial encounter
- T46.7X2D Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter
- T46.7X2S Poisoning by peripheral vasodilators, intentional self-harm, sequela
T46.7X3 Poisoning by peripheral vasodilators, assault
- T46.7X3A Poisoning by peripheral vasodilators, assault, initial encounter
- T46.7X3D Poisoning by peripheral vasodilators, assault, subsequent encounter
- T46.7X3S Poisoning by peripheral vasodilators, assault, sequela
T46.7X4 Poisoning by peripheral vasodilators, undetermined
- T46.7X4A Poisoning by peripheral vasodilators, undetermined, initial encounter
- T46.7X4D Poisoning by peripheral vasodilators, undetermined, subsequent encounter
- T46.7X4S Poisoning by peripheral vasodilators, undetermined, sequela
T46.7X5 Adverse effect of peripheral vasodilators
- T46.7X5A Adverse effect of peripheral vasodilators, initial encounter
- T46.7X5D Adverse effect of peripheral vasodilators, subsequent encounter
- T46.7X5S Adverse effect of peripheral vasodilators, sequela
T46.7X6 Underdosing of peripheral vasodilators
- T46.7X6A Underdosing of peripheral vasodilators, initial encounter
- T46.7X6D Underdosing of peripheral vasodilators, subsequent encounter
- T46.7X6S Underdosing of peripheral vasodilators, sequela
T46.8 Poisoning by, adverse effect of and underdosing of antivaricose drugs, including sclerosing agents
T46.8X Poisoning by, adverse effect of and underdosing of antivaricose drugs, including sclerosing agents
T46.8X1 Poisoning by antivaricose drugs, including sclerosing agents, accidental (unintentional)
- T46.8X1A Poisoning by antivaricose drugs, including sclerosing agents, accidental (unintentional), initial encounter
- T46.8X1D Poisoning by antivaricose drugs, including sclerosing agents, accidental (unintentional), subsequent encounter
- T46.8X1S Poisoning by antivaricose drugs, including sclerosing agents, accidental (unintentional), sequela
T46.8X2 Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm
- T46.8X2A Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter
- T46.8X2D Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter
- T46.8X2S Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela
T46.8X3 Poisoning by antivaricose drugs, including sclerosing agents, assault
- T46.8X3A Poisoning by antivaricose drugs, including sclerosing agents, assault, initial encounter
- T46.8X3D Poisoning by antivaricose drugs, including sclerosing agents, assault, subsequent encounter
- T46.8X3S Poisoning by antivaricose drugs, including sclerosing agents, assault, sequela
T46.8X4 Poisoning by antivaricose drugs, including sclerosing agents, undetermined
- T46.8X4A Poisoning by antivaricose drugs, including sclerosing agents, undetermined, initial encounter
- T46.8X4D Poisoning by antivaricose drugs, including sclerosing agents, undetermined, subsequent encounter
- T46.8X4S Poisoning by antivaricose drugs, including sclerosing agents, undetermined, sequela
T46.8X5 Adverse effect of antivaricose drugs, including sclerosing agents
- T46.8X5A Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
- T46.8X5D Adverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter
- T46.8X5S Adverse effect of antivaricose drugs, including sclerosing agents, sequela
T46.8X6 Underdosing of antivaricose drugs, including sclerosing agents
- T46.8X6A Underdosing of antivaricose drugs, including sclerosing agents, initial encounter
- T46.8X6D Underdosing of antivaricose drugs, including sclerosing agents, subsequent encounter
- T46.8X6S Underdosing of antivaricose drugs, including sclerosing agents, sequela
T46.9 Poisoning by, adverse effect of and underdosing of other and unspecified agents primarily affecting the cardiovascular system
T46.90 Poisoning by, adverse effect of and underdosing of unspecified agents primarily affecting the cardiovascular system
T46.901 Poisoning by unspecified agents primarily affecting the cardiovascular system, accidental (unintentional)
- T46.901A Poisoning by unspecified agents primarily affecting the cardiovascular system, accidental (unintentional), initial encounter
- T46.901D Poisoning by unspecified agents primarily affecting the cardiovascular system, accidental (unintentional), subsequent encounter
- T46.901S Poisoning by unspecified agents primarily affecting the cardiovascular system, accidental (unintentional), sequela
T46.902 Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm
- T46.902A Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter
- T46.902D Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter
- T46.902S Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela
T46.903 Poisoning by unspecified agents primarily affecting the cardiovascular system, assault
- T46.903A Poisoning by unspecified agents primarily affecting the cardiovascular system, assault, initial encounter
- T46.903D Poisoning by unspecified agents primarily affecting the cardiovascular system, assault, subsequent encounter
- T46.903S Poisoning by unspecified agents primarily affecting the cardiovascular system, assault, sequela
T46.904 Poisoning by unspecified agents primarily affecting the cardiovascular system, undetermined
- T46.904A Poisoning by unspecified agents primarily affecting the cardiovascular system, undetermined, initial encounter
- T46.904D Poisoning by unspecified agents primarily affecting the cardiovascular system, undetermined, subsequent encounter
- T46.904S Poisoning by unspecified agents primarily affecting the cardiovascular system, undetermined, sequela
T46.905 Adverse effect of unspecified agents primarily affecting the cardiovascular system
- T46.905A Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
- T46.905D Adverse effect of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
- T46.905S Adverse effect of unspecified agents primarily affecting the cardiovascular system, sequela
T46.906 Underdosing of unspecified agents primarily affecting the cardiovascular system
- T46.906A Underdosing of unspecified agents primarily affecting the cardiovascular system, initial encounter
- T46.906D Underdosing of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
- T46.906S Underdosing of unspecified agents primarily affecting the cardiovascular system, sequela
T46.99 Poisoning by, adverse effect of and underdosing of other agents primarily affecting the cardiovascular system
T46.991 Poisoning by other agents primarily affecting the cardiovascular system, accidental (unintentional)
- T46.991A Poisoning by other agents primarily affecting the cardiovascular system, accidental (unintentional), initial encounter
- T46.991D Poisoning by other agents primarily affecting the cardiovascular system, accidental (unintentional), subsequent encounter
- T46.991S Poisoning by other agents primarily affecting the cardiovascular system, accidental (unintentional), sequela
T46.992 Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm
- T46.992A Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter
- T46.992D Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter
- T46.992S Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela
T46.993 Poisoning by other agents primarily affecting the cardiovascular system, assault
- T46.993A Poisoning by other agents primarily affecting the cardiovascular system, assault, initial encounter
- T46.993D Poisoning by other agents primarily affecting the cardiovascular system, assault, subsequent encounter
- T46.993S Poisoning by other agents primarily affecting the cardiovascular system, assault, sequela
T46.994 Poisoning by other agents primarily affecting the cardiovascular system, undetermined
- T46.994A Poisoning by other agents primarily affecting the cardiovascular system, undetermined, initial encounter
- T46.994D Poisoning by other agents primarily affecting the cardiovascular system, undetermined, subsequent encounter
- T46.994S Poisoning by other agents primarily affecting the cardiovascular system, undetermined, sequela
T46.995 Adverse effect of other agents primarily affecting the cardiovascular system
- T46.995A Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
- T46.995D Adverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter
- T46.995S Adverse effect of other agents primarily affecting the cardiovascular system, sequela
T46.996 Underdosing of other agents primarily affecting the cardiovascular system
- T46.996A Underdosing of other agents primarily affecting the cardiovascular system, initial encounter
- T46.996D Underdosing of other agents primarily affecting the cardiovascular system, subsequent encounter
- T46.996S Underdosing of other agents primarily affecting the cardiovascular system, sequela
Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46)